Sera Prognostics, Inc. (NASDAQ: SERA) Stock Competitors & Peer Comparison
See SERA's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for SERA and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SERA | $2.04 | -2.86% | 79.8M | -3.22 | -$0.65 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.73% |
| TMO | $574.30 | -0.43% | 213.4B | 24.79 | $23.16 | +0.31% |
| DHR | $194.98 | -0.61% | 137.1B | 24.45 | $7.98 | +0.73% |
| IDXX | $559.07 | +0.05% | 44.1B | 41.17 | $13.58 | N/A |
| A | $138.37 | -0.25% | 39.1B | 23.82 | $5.81 | +0.73% |
| IQV | $235.02 | -1.16% | 38.7B | 19.38 | $12.13 | N/A |
| NTRA | $267.76 | -0.70% | 38.3B | -168.40 | -$1.59 | N/A |
| ILMN | $205.10 | +0.00% | 31B | 40.78 | $5.03 | N/A |
| MTD | $1,416.30 | +2.59% | 28.6B | 32.58 | $43.51 | N/A |
Stock Comparison
Danaher Corporation (NYSE: DHR-PB)
SERA vs DHR-PB Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, SERA's ROE is -0.41%, compared to DHR-PB's ROE of +0.08%. Regarding short-term risk, SERA is more volatile compared to DHR-PB. This indicates higher risk in terms of short-term price fluctuations for SERA.Check DHR-PB's competition here
Thermo Fisher Scientific Inc. (NYSE: TMO)
SERA vs TMO Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, TMO has a market cap of 213.4B. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while TMO trades at $574.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas TMO's P/E ratio is 24.79. In terms of profitability, SERA's ROE is -0.41%, compared to TMO's ROE of +0.13%. Regarding short-term risk, SERA is more volatile compared to TMO. This indicates higher risk in terms of short-term price fluctuations for SERA.Check TMO's competition here
Danaher Corporation (NYSE: DHR)
SERA vs DHR Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, DHR has a market cap of 137.1B. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while DHR trades at $194.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas DHR's P/E ratio is 24.45. In terms of profitability, SERA's ROE is -0.41%, compared to DHR's ROE of +0.08%. Regarding short-term risk, SERA is more volatile compared to DHR. This indicates higher risk in terms of short-term price fluctuations for SERA.Check DHR's competition here
IDEXX Laboratories, Inc. (NASDAQ: IDXX)
SERA vs IDXX Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, IDXX has a market cap of 44.1B. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while IDXX trades at $559.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas IDXX's P/E ratio is 41.17. In terms of profitability, SERA's ROE is -0.41%, compared to IDXX's ROE of +0.71%. Regarding short-term risk, SERA is more volatile compared to IDXX. This indicates higher risk in terms of short-term price fluctuations for SERA.Check IDXX's competition here
Agilent Technologies, Inc. (NYSE: A)
SERA vs A Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, A has a market cap of 39.1B. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while A trades at $138.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas A's P/E ratio is 23.82. In terms of profitability, SERA's ROE is -0.41%, compared to A's ROE of +0.21%. Regarding short-term risk, SERA is more volatile compared to A. This indicates higher risk in terms of short-term price fluctuations for SERA.Check A's competition here
IQVIA Holdings Inc. (NYSE: IQV)
SERA vs IQV Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, IQV has a market cap of 38.7B. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while IQV trades at $235.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas IQV's P/E ratio is 19.38. In terms of profitability, SERA's ROE is -0.41%, compared to IQV's ROE of +0.22%. Regarding short-term risk, SERA is more volatile compared to IQV. This indicates higher risk in terms of short-term price fluctuations for SERA.Check IQV's competition here
Natera, Inc. (NASDAQ: NTRA)
SERA vs NTRA Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, NTRA has a market cap of 38.3B. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while NTRA trades at $267.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas NTRA's P/E ratio is -168.40. In terms of profitability, SERA's ROE is -0.41%, compared to NTRA's ROE of -0.15%. Regarding short-term risk, SERA is more volatile compared to NTRA. This indicates higher risk in terms of short-term price fluctuations for SERA.Check NTRA's competition here
Illumina, Inc. (NASDAQ: ILMN)
SERA vs ILMN Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, ILMN has a market cap of 31B. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while ILMN trades at $205.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas ILMN's P/E ratio is 40.78. In terms of profitability, SERA's ROE is -0.41%, compared to ILMN's ROE of +0.31%. Regarding short-term risk, SERA is less volatile compared to ILMN. This indicates lower risk in terms of short-term price fluctuations for SERA.Check ILMN's competition here
Mettler-Toledo International Inc. (NYSE: MTD)
SERA vs MTD Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, MTD has a market cap of 28.6B. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while MTD trades at $1,416.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas MTD's P/E ratio is 32.58. In terms of profitability, SERA's ROE is -0.41%, compared to MTD's ROE of -12.00%. Regarding short-term risk, SERA is less volatile compared to MTD. This indicates lower risk in terms of short-term price fluctuations for SERA.Check MTD's competition here
Quest Diagnostics Incorporated (NYSE: DGX)
SERA vs DGX Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, DGX has a market cap of 25.7B. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while DGX trades at $233.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas DGX's P/E ratio is 22.98. In terms of profitability, SERA's ROE is -0.41%, compared to DGX's ROE of +0.14%. Regarding short-term risk, SERA is more volatile compared to DGX. This indicates higher risk in terms of short-term price fluctuations for SERA.Check DGX's competition here
Labcorp Holdings Inc. (NYSE: LH)
SERA vs LH Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, LH has a market cap of 25.4B. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while LH trades at $309.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas LH's P/E ratio is 18.36. In terms of profitability, SERA's ROE is -0.41%, compared to LH's ROE of +0.12%. Regarding short-term risk, SERA is more volatile compared to LH. This indicates higher risk in terms of short-term price fluctuations for SERA.Check LH's competition here
Waters Corporation (NYSE: WAT)
SERA vs WAT Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, WAT has a market cap of 24.6B. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while WAT trades at $377.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas WAT's P/E ratio is 27.78. In terms of profitability, SERA's ROE is -0.41%, compared to WAT's ROE of +0.08%. Regarding short-term risk, SERA is more volatile compared to WAT. This indicates higher risk in terms of short-term price fluctuations for SERA.Check WAT's competition here
Guardant Health, Inc. (NASDAQ: GH)
SERA vs GH Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, GH has a market cap of 21.5B. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while GH trades at $161.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas GH's P/E ratio is -62.79. In terms of profitability, SERA's ROE is -0.41%, compared to GH's ROE of +2.11%. Regarding short-term risk, SERA is less volatile compared to GH. This indicates lower risk in terms of short-term price fluctuations for SERA.Check GH's competition here
Exact Sciences Corporation (NASDAQ: EXAS)
SERA vs EXAS Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas EXAS's P/E ratio is -95.37. In terms of profitability, SERA's ROE is -0.41%, compared to EXAS's ROE of -0.09%. Regarding short-term risk, SERA is more volatile compared to EXAS. This indicates higher risk in terms of short-term price fluctuations for SERA.Check EXAS's competition here
Illumina, Inc. Common Stock Ex-distribution When-Issued (NASDAQ: ILMNV)
SERA vs ILMNV Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while ILMNV trades at $107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas ILMNV's P/E ratio is N/A. In terms of profitability, SERA's ROE is -0.41%, compared to ILMNV's ROE of N/A. Regarding short-term risk, SERA is more volatile compared to ILMNV. This indicates higher risk in terms of short-term price fluctuations for SERA.Check ILMNV's competition here
Medpace Holdings, Inc. (NASDAQ: MEDP)
SERA vs MEDP Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, MEDP has a market cap of 16.1B. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while MEDP trades at $577.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas MEDP's P/E ratio is 36.27. In terms of profitability, SERA's ROE is -0.41%, compared to MEDP's ROE of +1.10%. Regarding short-term risk, SERA is more volatile compared to MEDP. This indicates higher risk in terms of short-term price fluctuations for SERA.Check MEDP's competition here
PerkinElmer, Inc. (NYSE: PKI)
SERA vs PKI Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas PKI's P/E ratio is 41.45. In terms of profitability, SERA's ROE is -0.41%, compared to PKI's ROE of +0.03%. Regarding short-term risk, SERA is more volatile compared to PKI. This indicates higher risk in terms of short-term price fluctuations for SERA.Check PKI's competition here
Revvity, Inc. (NYSE: RVTY)
SERA vs RVTY Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, RVTY has a market cap of 12.6B. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while RVTY trades at $112.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas RVTY's P/E ratio is 21.98. In terms of profitability, SERA's ROE is -0.41%, compared to RVTY's ROE of +0.03%. Regarding short-term risk, SERA is more volatile compared to RVTY. This indicates higher risk in terms of short-term price fluctuations for SERA.Check RVTY's competition here
ICON Public Limited Company (NASDAQ: ICLR)
SERA vs ICLR Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, ICLR has a market cap of 12.5B. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while ICLR trades at $163.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas ICLR's P/E ratio is 13.34. In terms of profitability, SERA's ROE is -0.41%, compared to ICLR's ROE of +0.04%. Regarding short-term risk, SERA is more volatile compared to ICLR. This indicates higher risk in terms of short-term price fluctuations for SERA.Check ICLR's competition here
Charles River Laboratories International, Inc. (NYSE: CRL)
SERA vs CRL Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, CRL has a market cap of 11.2B. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while CRL trades at $232.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas CRL's P/E ratio is 23.25. In terms of profitability, SERA's ROE is -0.41%, compared to CRL's ROE of -0.06%. Regarding short-term risk, SERA is more volatile compared to CRL. This indicates higher risk in terms of short-term price fluctuations for SERA.Check CRL's competition here
Qiagen N.V. (NYSE: QGEN)
SERA vs QGEN Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, QGEN has a market cap of 8.5B. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while QGEN trades at $41.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas QGEN's P/E ratio is 17.25. In terms of profitability, SERA's ROE is -0.41%, compared to QGEN's ROE of +0.11%. Regarding short-term risk, SERA is more volatile compared to QGEN. This indicates higher risk in terms of short-term price fluctuations for SERA.Check QGEN's competition here
BillionToOne, Inc. (NASDAQ: BLLN)
SERA vs BLLN Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, BLLN has a market cap of 6.4B. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while BLLN trades at $138.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas BLLN's P/E ratio is 252.00. In terms of profitability, SERA's ROE is -0.41%, compared to BLLN's ROE of +0.08%. Regarding short-term risk, SERA is more volatile compared to BLLN. This indicates higher risk in terms of short-term price fluctuations for SERA.Check BLLN's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
SERA vs TWST Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, TWST has a market cap of 5.7B. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while TWST trades at $91.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas TWST's P/E ratio is -42.98. In terms of profitability, SERA's ROE is -0.41%, compared to TWST's ROE of -0.17%. Regarding short-term risk, SERA is similarly volatile compared to TWST. This indicates similar risk in terms of short-term price fluctuations for SERA.Check TWST's competition here
Sotera Health Company (NASDAQ: SHC)
SERA vs SHC Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, SHC has a market cap of 5.1B. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while SHC trades at $17.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas SHC's P/E ratio is 19.84. In terms of profitability, SERA's ROE is -0.41%, compared to SHC's ROE of +0.21%. Regarding short-term risk, SERA is more volatile compared to SHC. This indicates higher risk in terms of short-term price fluctuations for SERA.Check SHC's competition here
RadNet, Inc. (NASDAQ: RDNT)
SERA vs RDNT Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, RDNT has a market cap of 5B. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while RDNT trades at $63.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas RDNT's P/E ratio is 138.65. In terms of profitability, SERA's ROE is -0.41%, compared to RDNT's ROE of -0.01%. Regarding short-term risk, SERA is more volatile compared to RDNT. This indicates higher risk in terms of short-term price fluctuations for SERA.Check RDNT's competition here
Syneos Health, Inc. (NASDAQ: SYNH)
SERA vs SYNH Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas SYNH's P/E ratio is 61.40. In terms of profitability, SERA's ROE is -0.41%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, SERA is more volatile compared to SYNH. This indicates higher risk in terms of short-term price fluctuations for SERA.Check SYNH's competition here
Veracyte, Inc. (NASDAQ: VCYT)
SERA vs VCYT Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, VCYT has a market cap of 3.7B. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while VCYT trades at $46.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas VCYT's P/E ratio is 23.16. In terms of profitability, SERA's ROE is -0.41%, compared to VCYT's ROE of +0.09%. Regarding short-term risk, SERA is less volatile compared to VCYT. This indicates lower risk in terms of short-term price fluctuations for SERA.Check VCYT's competition here
Olink Holding AB (publ) (NASDAQ: OLK)
SERA vs OLK Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas OLK's P/E ratio is -96.59. In terms of profitability, SERA's ROE is -0.41%, compared to OLK's ROE of -0.07%. Regarding short-term risk, SERA is more volatile compared to OLK. This indicates higher risk in terms of short-term price fluctuations for SERA.Check OLK's competition here
Neogen Corporation (NASDAQ: NEOG)
SERA vs NEOG Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, NEOG has a market cap of 2.6B. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while NEOG trades at $12.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas NEOG's P/E ratio is 43.00. In terms of profitability, SERA's ROE is -0.41%, compared to NEOG's ROE of -0.00%. Regarding short-term risk, SERA is less volatile compared to NEOG. This indicates lower risk in terms of short-term price fluctuations for SERA.Check NEOG's competition here
CareDx, Inc (NASDAQ: CDNA)
SERA vs CDNA Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, CDNA has a market cap of 2.3B. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while CDNA trades at $43.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas CDNA's P/E ratio is 52.04. In terms of profitability, SERA's ROE is -0.41%, compared to CDNA's ROE of +0.33%. Regarding short-term risk, SERA is less volatile compared to CDNA. This indicates lower risk in terms of short-term price fluctuations for SERA.Check CDNA's competition here
Personalis, Inc. (NASDAQ: PSNL)
SERA vs PSNL Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, PSNL has a market cap of 1.4B. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while PSNL trades at $12.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas PSNL's P/E ratio is -12.41. In terms of profitability, SERA's ROE is -0.41%, compared to PSNL's ROE of -0.44%. Regarding short-term risk, SERA is more volatile compared to PSNL. This indicates higher risk in terms of short-term price fluctuations for SERA.Check PSNL's competition here
Castle Biosciences, Inc. (NASDAQ: CSTL)
SERA vs CSTL Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, CSTL has a market cap of 849.2M. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while CSTL trades at $28.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas CSTL's P/E ratio is -63.64. In terms of profitability, SERA's ROE is -0.41%, compared to CSTL's ROE of -0.04%. Regarding short-term risk, SERA is less volatile compared to CSTL. This indicates lower risk in terms of short-term price fluctuations for SERA.Check CSTL's competition here
GRAIL, Inc. Common Stock (NASDAQ: GRALV)
SERA vs GRALV Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas GRALV's P/E ratio is N/A. In terms of profitability, SERA's ROE is -0.41%, compared to GRALV's ROE of N/A. Regarding short-term risk, SERA is less volatile compared to GRALV. This indicates lower risk in terms of short-term price fluctuations for SERA.Check GRALV's competition here
Fulgent Genetics, Inc. (NASDAQ: FLGT)
SERA vs FLGT Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, FLGT has a market cap of 470M. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while FLGT trades at $16.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas FLGT's P/E ratio is 1655.00. In terms of profitability, SERA's ROE is -0.41%, compared to FLGT's ROE of -0.08%. Regarding short-term risk, SERA is less volatile compared to FLGT. This indicates lower risk in terms of short-term price fluctuations for SERA.Check FLGT's competition here
Global Cord Blood Corporation (NYSE: CO)
SERA vs CO Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas CO's P/E ratio is 5.06. In terms of profitability, SERA's ROE is -0.41%, compared to CO's ROE of +0.11%. Regarding short-term risk, SERA is less volatile compared to CO. This indicates lower risk in terms of short-term price fluctuations for SERA.Check CO's competition here
NeoGenomics, Inc. (NASDAQ: NEO)
SERA vs NEO Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, NEO has a market cap of 392.9M. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while NEO trades at $15.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas NEO's P/E ratio is 117.62. In terms of profitability, SERA's ROE is -0.41%, compared to NEO's ROE of -0.06%. Regarding short-term risk, SERA is more volatile compared to NEO. This indicates higher risk in terms of short-term price fluctuations for SERA.Check NEO's competition here
Prenetics Global Limited (NASDAQ: PRENW)
SERA vs PRENW Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, PRENW has a market cap of 360.8M. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while PRENW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas PRENW's P/E ratio is N/A. In terms of profitability, SERA's ROE is -0.41%, compared to PRENW's ROE of -0.47%. Regarding short-term risk, SERA is more volatile compared to PRENW. This indicates higher risk in terms of short-term price fluctuations for SERA.Check PRENW's competition here
Prenetics Global Limited (NASDAQ: PRE)
SERA vs PRE Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, PRE has a market cap of 316.9M. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while PRE trades at $18.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas PRE's P/E ratio is -9.05. In terms of profitability, SERA's ROE is -0.41%, compared to PRE's ROE of -0.47%. Regarding short-term risk, SERA is less volatile compared to PRE. This indicates lower risk in terms of short-term price fluctuations for SERA.Check PRE's competition here
Standard BioTools Inc. (NASDAQ: FLDM)
SERA vs FLDM Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas FLDM's P/E ratio is -4.74. In terms of profitability, SERA's ROE is -0.41%, compared to FLDM's ROE of +0.17%. Regarding short-term risk, SERA is less volatile compared to FLDM. This indicates lower risk in terms of short-term price fluctuations for SERA.Check FLDM's competition here
Myriad Genetics, Inc. (NASDAQ: MYGN)
SERA vs MYGN Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, MYGN has a market cap of 270.1M. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while MYGN trades at $2.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas MYGN's P/E ratio is -22.00. In terms of profitability, SERA's ROE is -0.41%, compared to MYGN's ROE of -0.33%. Regarding short-term risk, SERA is less volatile compared to MYGN. This indicates lower risk in terms of short-term price fluctuations for SERA.Check MYGN's competition here
Trinity Biotech plc (NASDAQ: TRIB)
SERA vs TRIB Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, TRIB has a market cap of 234.9M. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while TRIB trades at $11.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas TRIB's P/E ratio is -3.01. In terms of profitability, SERA's ROE is -0.41%, compared to TRIB's ROE of +0.68%. Regarding short-term risk, SERA is less volatile compared to TRIB. This indicates lower risk in terms of short-term price fluctuations for SERA.Check TRIB's competition here
Biodesix, Inc. (NASDAQ: BDSX)
SERA vs BDSX Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, BDSX has a market cap of 172.6M. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while BDSX trades at $21.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas BDSX's P/E ratio is -5.22. In terms of profitability, SERA's ROE is -0.41%, compared to BDSX's ROE of -21.01%. Regarding short-term risk, SERA is more volatile compared to BDSX. This indicates higher risk in terms of short-term price fluctuations for SERA.Check BDSX's competition here
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX)
SERA vs IMDX Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, IMDX has a market cap of 150.1M. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while IMDX trades at $4.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas IMDX's P/E ratio is -3.91. In terms of profitability, SERA's ROE is -0.41%, compared to IMDX's ROE of +3.81%. Regarding short-term risk, SERA is more volatile compared to IMDX. This indicates higher risk in terms of short-term price fluctuations for SERA.Check IMDX's competition here
Genetron Holdings Limited (NASDAQ: GTH)
SERA vs GTH Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas GTH's P/E ratio is -1.11. In terms of profitability, SERA's ROE is -0.41%, compared to GTH's ROE of -1.01%. Regarding short-term risk, SERA is more volatile compared to GTH. This indicates higher risk in terms of short-term price fluctuations for SERA.Check GTH's competition here
Genetic Technologies Limited (NASDAQ: GENE)
SERA vs GENE Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas GENE's P/E ratio is -38.25. In terms of profitability, SERA's ROE is -0.41%, compared to GENE's ROE of -1.85%. Regarding short-term risk, SERA is more volatile compared to GENE. This indicates higher risk in terms of short-term price fluctuations for SERA.Check GENE's competition here
Exagen Inc. (NASDAQ: XGN)
SERA vs XGN Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, XGN has a market cap of 109.4M. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while XGN trades at $4.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas XGN's P/E ratio is -6.12. In terms of profitability, SERA's ROE is -0.41%, compared to XGN's ROE of -1.14%. Regarding short-term risk, SERA is less volatile compared to XGN. This indicates lower risk in terms of short-term price fluctuations for SERA.Check XGN's competition here
Atlantic International Corp. (NASDAQ: ATLN)
SERA vs ATLN Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, ATLN has a market cap of 73.2M. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while ATLN trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas ATLN's P/E ratio is -0.68. In terms of profitability, SERA's ROE is -0.41%, compared to ATLN's ROE of +14.94%. Regarding short-term risk, SERA is less volatile compared to ATLN. This indicates lower risk in terms of short-term price fluctuations for SERA.Check ATLN's competition here
DarioHealth Corp. (NASDAQ: DRIO)
SERA vs DRIO Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, DRIO has a market cap of 53.2M. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while DRIO trades at $7.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas DRIO's P/E ratio is -1.24. In terms of profitability, SERA's ROE is -0.41%, compared to DRIO's ROE of +0.93%. Regarding short-term risk, SERA is less volatile compared to DRIO. This indicates lower risk in terms of short-term price fluctuations for SERA.Check DRIO's competition here
Precipio, Inc. (NASDAQ: PRPO)
SERA vs PRPO Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, PRPO has a market cap of 38.7M. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while PRPO trades at $21.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas PRPO's P/E ratio is -83.27. In terms of profitability, SERA's ROE is -0.41%, compared to PRPO's ROE of -0.07%. Regarding short-term risk, SERA is less volatile compared to PRPO. This indicates lower risk in terms of short-term price fluctuations for SERA.Check PRPO's competition here
Akumin Inc. (NASDAQ: AKU)
SERA vs AKU Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas AKU's P/E ratio is -0.13. In terms of profitability, SERA's ROE is -0.41%, compared to AKU's ROE of -5.32%. Regarding short-term risk, SERA is less volatile compared to AKU. This indicates lower risk in terms of short-term price fluctuations for SERA.Check AKU's competition here
MDxHealth S.A. (NASDAQ: MDXH)
SERA vs MDXH Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, MDXH has a market cap of 21.5M. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while MDXH trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas MDXH's P/E ratio is -1.10. In terms of profitability, SERA's ROE is -0.41%, compared to MDXH's ROE of +4.03%. Regarding short-term risk, SERA is more volatile compared to MDXH. This indicates higher risk in terms of short-term price fluctuations for SERA.Check MDXH's competition here
Chembio Diagnostics, Inc. (NASDAQ: CEMI)
SERA vs CEMI Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas CEMI's P/E ratio is -0.63. In terms of profitability, SERA's ROE is -0.41%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, SERA is more volatile compared to CEMI. This indicates higher risk in terms of short-term price fluctuations for SERA.Check CEMI's competition here
Enzo Biochem, Inc. (NYSE: ENZ)
SERA vs ENZ Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas ENZ's P/E ratio is -2.24. In terms of profitability, SERA's ROE is -0.41%, compared to ENZ's ROE of -0.10%. Regarding short-term risk, SERA is less volatile compared to ENZ. This indicates lower risk in terms of short-term price fluctuations for SERA.Check ENZ's competition here
Psychemedics Corporation (NASDAQ: PMD)
SERA vs PMD Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas PMD's P/E ratio is -5.24. In terms of profitability, SERA's ROE is -0.41%, compared to PMD's ROE of -0.32%. Regarding short-term risk, SERA is more volatile compared to PMD. This indicates higher risk in terms of short-term price fluctuations for SERA.Check PMD's competition here
23andMe Holding Co. (NASDAQ: ME)
SERA vs ME Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas ME's P/E ratio is -0.03. In terms of profitability, SERA's ROE is -0.41%, compared to ME's ROE of -42.03%. Regarding short-term risk, SERA is more volatile compared to ME. This indicates higher risk in terms of short-term price fluctuations for SERA.Check ME's competition here
Mainz Biomed B.V. (NASDAQ: MYNZ)
SERA vs MYNZ Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas MYNZ's P/E ratio is -0.68. In terms of profitability, SERA's ROE is -0.41%, compared to MYNZ's ROE of -10.25%. Regarding short-term risk, SERA is less volatile compared to MYNZ. This indicates lower risk in terms of short-term price fluctuations for SERA.Check MYNZ's competition here
Quantum Cyber N.V. (NASDAQ: QUCY)
SERA vs QUCY Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, QUCY has a market cap of 14.3M. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while QUCY trades at $1.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas QUCY's P/E ratio is -0.05. In terms of profitability, SERA's ROE is -0.41%, compared to QUCY's ROE of -3.26%. Regarding short-term risk, SERA is more volatile compared to QUCY. This indicates higher risk in terms of short-term price fluctuations for SERA.Check QUCY's competition here
Bionano Genomics, Inc. (NASDAQ: BNGO)
SERA vs BNGO Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, BNGO has a market cap of 12.3M. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while BNGO trades at $1.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas BNGO's P/E ratio is -0.24. In terms of profitability, SERA's ROE is -0.41%, compared to BNGO's ROE of -0.71%. Regarding short-term risk, SERA is less volatile compared to BNGO. This indicates lower risk in terms of short-term price fluctuations for SERA.Check BNGO's competition here
Check-Cap Ltd. (NASDAQ: CHEK)
SERA vs CHEK Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas CHEK's P/E ratio is -0.43. In terms of profitability, SERA's ROE is -0.41%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, SERA is more volatile compared to CHEK. This indicates higher risk in terms of short-term price fluctuations for SERA.Check CHEK's competition here
Centogene N.V. (NASDAQ: CNTG)
SERA vs CNTG Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas CNTG's P/E ratio is -0.23. In terms of profitability, SERA's ROE is -0.41%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, SERA is more volatile compared to CNTG. This indicates higher risk in terms of short-term price fluctuations for SERA.Check CNTG's competition here
Burning Rock Biotech Limited (NASDAQ: BNR)
SERA vs BNR Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, BNR has a market cap of 9.3M. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while BNR trades at $8.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas BNR's P/E ratio is -10.73. In terms of profitability, SERA's ROE is -0.41%, compared to BNR's ROE of -0.11%. Regarding short-term risk, SERA is more volatile compared to BNR. This indicates higher risk in terms of short-term price fluctuations for SERA.Check BNR's competition here
Advanced Biomed Inc. Common Stock (NASDAQ: ADVB)
SERA vs ADVB Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, ADVB has a market cap of 8.7M. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while ADVB trades at $8.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas ADVB's P/E ratio is -72.73. In terms of profitability, SERA's ROE is -0.41%, compared to ADVB's ROE of -0.21%. Regarding short-term risk, SERA is less volatile compared to ADVB. This indicates lower risk in terms of short-term price fluctuations for SERA.Check ADVB's competition here
Check-Cap Ltd. Ordinary Share (NASDAQ: MBAI)
SERA vs MBAI Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, MBAI has a market cap of 7.4M. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while MBAI trades at $1.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas MBAI's P/E ratio is 1.58. In terms of profitability, SERA's ROE is -0.41%, compared to MBAI's ROE of +4.17%. Regarding short-term risk, SERA is less volatile compared to MBAI. This indicates lower risk in terms of short-term price fluctuations for SERA.Check MBAI's competition here
Applied DNA Sciences, Inc. (NASDAQ: APDN)
SERA vs APDN Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas APDN's P/E ratio is -0.10. In terms of profitability, SERA's ROE is -0.41%, compared to APDN's ROE of -6.53%. Regarding short-term risk, SERA is less volatile compared to APDN. This indicates lower risk in terms of short-term price fluctuations for SERA.Check APDN's competition here
Invitae Corporation (NYSE: NVTA)
SERA vs NVTA Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas NVTA's P/E ratio is -0.00. In terms of profitability, SERA's ROE is -0.41%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, SERA is less volatile compared to NVTA. This indicates lower risk in terms of short-term price fluctuations for SERA.Check NVTA's competition here
LumiraDx Limited (NASDAQ: LMDX)
SERA vs LMDX Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas LMDX's P/E ratio is -0.01. In terms of profitability, SERA's ROE is -0.41%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, SERA is less volatile compared to LMDX. This indicates lower risk in terms of short-term price fluctuations for SERA.Check LMDX's competition here
LumiraDx Limited (NASDAQ: LMDXW)
SERA vs LMDXW Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, SERA's ROE is -0.41%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, SERA is less volatile compared to LMDXW. This indicates lower risk in terms of short-term price fluctuations for SERA.Check LMDXW's competition here
ENDRA Life Sciences Inc. (NASDAQ: NDRA)
SERA vs NDRA Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, NDRA has a market cap of 3.6M. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while NDRA trades at $4.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas NDRA's P/E ratio is -0.61. In terms of profitability, SERA's ROE is -0.41%, compared to NDRA's ROE of -5.13%. Regarding short-term risk, SERA is less volatile compared to NDRA. This indicates lower risk in terms of short-term price fluctuations for SERA.Check NDRA's competition here
DermTech, Inc. (NASDAQ: DMTK)
SERA vs DMTK Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas DMTK's P/E ratio is -0.04. In terms of profitability, SERA's ROE is -0.41%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, SERA is less volatile compared to DMTK. This indicates lower risk in terms of short-term price fluctuations for SERA.Check DMTK's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAF)
SERA vs BIAF Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, BIAF has a market cap of 2.8M. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while BIAF trades at $0.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas BIAF's P/E ratio is -0.07. In terms of profitability, SERA's ROE is -0.41%, compared to BIAF's ROE of -3.59%. Regarding short-term risk, SERA is less volatile compared to BIAF. This indicates lower risk in terms of short-term price fluctuations for SERA.Check BIAF's competition here
Inotiv, Inc. (NASDAQ: NOTV)
SERA vs NOTV Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, NOTV has a market cap of 2.8M. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while NOTV trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas NOTV's P/E ratio is -0.03. In terms of profitability, SERA's ROE is -0.41%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, SERA is less volatile compared to NOTV. This indicates lower risk in terms of short-term price fluctuations for SERA.Check NOTV's competition here
SeqLL Inc. (NASDAQ: SQL)
SERA vs SQL Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas SQL's P/E ratio is -0.40. In terms of profitability, SERA's ROE is -0.41%, compared to SQL's ROE of +38.02%. Regarding short-term risk, SERA is less volatile compared to SQL. This indicates lower risk in terms of short-term price fluctuations for SERA.Check SQL's competition here
Aspira Women's Health Inc. (NASDAQ: AWH)
SERA vs AWH Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas AWH's P/E ratio is -0.09. In terms of profitability, SERA's ROE is -0.41%, compared to AWH's ROE of +2.03%. Regarding short-term risk, SERA is more volatile compared to AWH. This indicates higher risk in terms of short-term price fluctuations for SERA.Check AWH's competition here
Intelligent Bio Solutions Inc. (NASDAQ: INBS)
SERA vs INBS Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, INBS has a market cap of 1.2M. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while INBS trades at $1.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas INBS's P/E ratio is -0.21. In terms of profitability, SERA's ROE is -0.41%, compared to INBS's ROE of -1.74%. Regarding short-term risk, SERA is less volatile compared to INBS. This indicates lower risk in terms of short-term price fluctuations for SERA.Check INBS's competition here
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM)
SERA vs HTGM Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas HTGM's P/E ratio is -0.03. In terms of profitability, SERA's ROE is -0.41%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, SERA is more volatile compared to HTGM. This indicates higher risk in terms of short-term price fluctuations for SERA.Check HTGM's competition here
Biocept, Inc. (NASDAQ: BIOC)
SERA vs BIOC Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas BIOC's P/E ratio is -0.01. In terms of profitability, SERA's ROE is -0.41%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, SERA is less volatile compared to BIOC. This indicates lower risk in terms of short-term price fluctuations for SERA.Check BIOC's competition here
iSpecimen Inc. (NASDAQ: ISPC)
SERA vs ISPC Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, ISPC has a market cap of 262.4K. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while ISPC trades at $1.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas ISPC's P/E ratio is -0.06. In terms of profitability, SERA's ROE is -0.41%, compared to ISPC's ROE of -5.85%. Regarding short-term risk, SERA is less volatile compared to ISPC. This indicates lower risk in terms of short-term price fluctuations for SERA.Check ISPC's competition here
SeqLL Inc. (NASDAQ: SQLLW)
SERA vs SQLLW Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, SQLLW has a market cap of 179.6K. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas SQLLW's P/E ratio is -0.00. In terms of profitability, SERA's ROE is -0.41%, compared to SQLLW's ROE of +38.02%. Regarding short-term risk, SERA is less volatile compared to SQLLW. This indicates lower risk in terms of short-term price fluctuations for SERA.Check SQLLW's competition here
Check-Cap Ltd (NASDAQ: CHEKZ)
SERA vs CHEKZ Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, SERA's ROE is -0.41%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, SERA is less volatile compared to CHEKZ. This indicates lower risk in terms of short-term price fluctuations for SERA.Check CHEKZ's competition here
Danaher Corporation (NYSE: DHR-PA)
SERA vs DHR-PA Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, SERA's ROE is -0.41%, compared to DHR-PA's ROE of +0.08%. Regarding short-term risk, SERA is more volatile compared to DHR-PA. This indicates higher risk in terms of short-term price fluctuations for SERA.Check DHR-PA's competition here
23andMe Holding Co. (NASDAQ: MEUSW)
SERA vs MEUSW Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas MEUSW's P/E ratio is N/A. In terms of profitability, SERA's ROE is -0.41%, compared to MEUSW's ROE of -42.03%. Regarding short-term risk, SERA is less volatile compared to MEUSW. This indicates lower risk in terms of short-term price fluctuations for SERA.Check MEUSW's competition here
PAREXEL Intl Corp. (NASDAQ: PRXL)
SERA vs PRXL Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, PRXL has a market cap of 0. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas PRXL's P/E ratio is 42.97. In terms of profitability, SERA's ROE is -0.41%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, SERA is more volatile compared to PRXL. This indicates higher risk in terms of short-term price fluctuations for SERA.Check PRXL's competition here
Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX)
SERA vs OCDX Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, OCDX has a market cap of 0. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas OCDX's P/E ratio is -42.28. In terms of profitability, SERA's ROE is -0.41%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, SERA is more volatile compared to OCDX. This indicates higher risk in terms of short-term price fluctuations for SERA.Check OCDX's competition here
BioNano Genomics, Inc. WT EXP 082123 (NASDAQ: BNGOW)
SERA vs BNGOW Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas BNGOW's P/E ratio is N/A. In terms of profitability, SERA's ROE is -0.41%, compared to BNGOW's ROE of -0.71%. Regarding short-term risk, SERA is less volatile compared to BNGOW. This indicates lower risk in terms of short-term price fluctuations for SERA.Check BNGOW's competition here
ENDRA Life Sciences Inc. Warrants (NASDAQ: NDRAW)
SERA vs NDRAW Comparison August 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 79.8M. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, SERA is priced at $2.04 on the NASDAQ, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.22, whereas NDRAW's P/E ratio is N/A. In terms of profitability, SERA's ROE is -0.41%, compared to NDRAW's ROE of -5.13%. Regarding short-term risk, SERA is less volatile compared to NDRAW. This indicates lower risk in terms of short-term price fluctuations for SERA.Check NDRAW's competition here